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Objective: This open, randomized and blinded parallel-group multicenter study evaluated
the  efﬁcacy of Actonel® (35 mg) plus calcium/vitamin D versus calcium/vitamin D alone for
preserving bone mineral density (BMD) in postmenopausal women with Colles fractures.
Methods: Patients with a Colles fracture for seven days were randomized to receive either
Actonel® (35 mg) once a week plus calcium/vitamin D (ACD group) or calcium/vitamin D
alone (CD group). The patients were evaluated after 90 and 180 days of treatment.
Results: 59 ACD patients and 56 CD patients completed all the evaluations. At the end of the
study, the BMD of the radius at the fracture location showed a negative change in the CD
group (32.8%). The loss of BMD in the ACD group (20.8%) was slightly less than that in the CD
group. There was a difference in the proportions of patients with BMD losses at the end of
the  study period in the two treatment groups, in favor of the ACD group, although this was
not  statistically signiﬁcant. There was no signiﬁcant difference in radiological identiﬁcationof  callus formation between the treatment groups. In the majority of the patients, the callus
could be radiologically identiﬁed after 90 days.
Conclusion: Postmenopausal women with Colles fractures who received risedronate sodium
plus  calcium/vitamin D did not show any signiﬁcant difference in BMD loss in forearm∗ Corresponding author.
E-mail: Lindomar@terra.com.br (L.G. Oliveira).
† In memoriam.
http://dx.doi.org/10.1016/j.rboe.2015.04.004
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fractures, in comparison with those who received calcium/vitamin D alone. Risedronate
a  protective effect regarding BMD loss due to immobilization. The time taken for fracture
consolidation to be achieved was unaffected.
©  2014 Sociedade Brasileira de Ortopedia e Traumatologia. Published by Elsevier Editora
Ltda. All rights reserved.
Uso  de  risedronato  na  consolidac¸ão e  formac¸ão  do  calo  na  fratura  de
Colles  em  mulheres  na  pós-menopausa  –  Estudo  Solid
Palavras-chave:
Consolidac¸ão da fratura
Fratura de Colles
Difosfonatos
r  e  s  u  m  o
Objetivo: Este estudo multicêntrico, randomizado, aberto, grupo paralelo avaliou a eﬁcá-
cia  de Actonel® 35 mg mais cálcio/vitamina D versus cálcio/vitamina D isoladamente na
preservac¸ão  da densidade mineral óssea (DMO) em mulheres pós-menopausadas com
fratura de Colles.
Métodos: Pacientes com fratura de Colles em sete dias foram aleatoriamente designadas
para  receber Actonel® 35 mg semanalmente mais cálcio/vitamina D (Grupo AO [GAO]) ou
cálcio/vitamina D (grupo O [GO]) isoladamente. As pacientes foram avaliadas após 90 e 180
dias  de tratamento.
Resultados: Completaram as avaliac¸ões 59 pacientes no GAO e 56 no OG. No ﬁm do estudo, a
DMO do rádio no local da fratura mostrou variac¸ão negativa no GO (32,8%) que foi discreta-
mente menor no GAO (20,8%), assim como uma perda menor na DMO no GAO comparado
com  o OG. Houve diferenc¸a na proporc¸ão de paciente com perda da DMO no ﬁm do estudo
nos  dois grupos de tratamento em favor do GAO, apesar de não estatisticamente signiﬁ-
cante. Não houve diferenc¸a signiﬁcativa na identiﬁcac¸ão radiológica da formac¸ão do calo
entre  os grupos de tratamento. Na maioria das pacientes a identiﬁcac¸ão radiológica do calo
ocorreu depois de 90 dias.
Conclusão: Mulheres pós-menopausadas com fratura de Colles que receberam risedronato
sódico, além do cálcio/vitamina D, comparado com cálcio/vitamina D não mostraram
diferenc¸a  signiﬁcativa na perda da DMO na fratura do antebrac¸o, com tendência de efeito
protetor do risedronato na perda da DMO devido à imobilizac¸ão. O tempo até a consolidac¸ão
da fratura não foi afetado.
© 2014 Sociedade Brasileira de Ortopedia e Traumatologia. Publicado por Elsevier
Editora Ltda. Todos os direitos reservados.
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in three of the four cortical areas identiﬁable by means of APntroduction
he potential for accelerating or improving the formation
f a callus and preventing progression of fractures to pseu-
arthrosis has been correlated with mechanical procedures
or stabilizing bone fragments. However, this reality has
hanges in the light of the proven efﬁcacy of physical methods
r medications.1
Bisphosphonates have been studied regarding their pos-
ible positive or negative inﬂuence on formation of bone
alluses. This gives rise to questions that relate to how bis-
hosphonates might interfere with bone consolidation; what
heir inﬂuence on the histology, morphology and biomechan-
cs of the callus might be; what the best time after the fracture
or starting medication would be; whether bisphosphonates
ight have any effect on consolidation among patients who
sed them previously, before the fracture; and whether all
ypes of bisphosphonates act in the same manner with regard
o formation of the bone callus.2–4
At therapeutic doses for osteoporosis, different bis-
hosphonates have not shown negative effects on boneconsolidation but have shown improvements to the biome-
chanical aspects of bone.5–9 Experimental studies using
risedronate have shown that consolidation occurs, without
any change to the time taken, but with bone callus of better
histological quality.10,11
The aims of the SOLID study were as follows: 1 – primary
aim: to evaluate the efﬁcacy of preservation of bone mineral
density (BMD) provided by 35 mg  of Actonel® in the proximal
forearm, named the region of interest (RI 33%), after 90 days
of treatment, based on the difference between treatments
(sodium risedronate plus calcium and vitamin D versus cal-
cium and vitamin D alone); 2 – secondary aim: to evaluate the
efﬁcacy of preservation of BMD provided by 35 mg of Actonel®
in the proximal forearm (RI 33%), after 180 days of treatment;
to evaluate the differences in ultradistal BMD between the
treatment groups, in the region of callus formation, after 90
and 180 days of treatment; to evaluate the radiological iden-
tiﬁcation of the callus, deﬁned by identifying the bone bridgeand lateral X-ray views during the follow-up; and to evaluate
safety.
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Materials  and  methods
Study  design
This was a comparative parallel-group open randomized mul-
ticenter phase IV study conducted in six study centers in
Brazil: Goiânia (one), Fortaleza (one), Niterói (one), São Luís do
Maranhão (one) and São Paulo (two). The study was approved
by the appropriate ethics committees and the patients gave
their free and informed consent in writing, before any pro-
cedures relating to the study were started. Furthermore, the
study was conducted in accordance with good clinical prac-
tices and with the ethical principles that originated from the
Declaration of Helsinki.
Each patient was evaluated over a 180-day period, through
seven evaluation visits: VO (baseline): visit made seven days
after Colles fracture occurred; VR, randomization visit (day
0), made seven days after the baseline; and subsequent vis-
its made 15 (V1), 30 (V2), 45 (V3), 90 (V4) and 180 (V5) days after
the randomization date. Among the visits, an interval of three
days was allowed.
Patients
Women who had been postmenopausal for at least two years
were eligible to participate if they presented a Colles fracture
that was conﬁrmed within a period of seven days before entry
into the study. The patients were stratiﬁed by age in a 1:1 ratio
(<65 and ≥65 years) and according to T-score ≤ −2.0 standard
deviations in the lumbar spine (L1–L4 and/or L2–L4) and/or
femoral neck and/or total femur and/or 33% radius.
The main inclusion and exclusion criteria were as follows:
Inclusion criteria: postmenopausal for at least two years;
Colles fracture conﬁrmed with occurrence seven days before
entry into the study; T-score ≤ −2.0 standard deviations in the
lumbar spine (L1–L4 and/or L2–L4) and/or femoral neck and/or
total femur and/or 33% radius.
Exclusion criteria: previous fracture in the same wrist or fore-
arm; fracture that, in the opinion of the orthopedic surgeon
or person responsible for the case, should only be treated
surgically; distal fracture of the radius or fractures in contralat-
eral bones that occurred previously or concomitantly, which
might impede comparisons of the BMD  evaluations over the
course of the study; use of medications concomitantly that
might affect the calcium metabolism; previous treatment with
bisphosphonates for more  than 12 months over the last 36
months; use of bisphosphonates for any period of time over
the last three months; cumulative use of bisphosphonates for
more than 36 months on any occasion; rheumatoid arthri-
tis or any other disease with involvement of the wrist; hyper
or hypothyroidism that is known to be stable, with or with-
out treatment; hypocalcemia, liver disease, kidney disease or
rheumatic diseases.
Study  treatmentsAt the randomization visit, the eligible patients were
designated to receive one of the two study treatments:
Actonel® + Oscal® group (GAO): 35 mg  of sodium risedronate1 5;5 0(3):274–282
once a week plus 1000 mg  of calcium and 400 IU of vitamin D
on six days a week (i.e. not on the day on which risedronate
would be taken); or Oscal® group (GO): 1000 mg  of calcium and
400 IU of vitamin D daily (i.e. seven days a week).
Efﬁcacy  assessments
Efﬁcacy was based on the changes seen in the T scores in
the proximal region of the forearm (33% of the region of the
radius), from the baseline to V4 (90 days) and V5 (180 days)
after the treatment and was expressed as percentages for the
two arms fractured and non-fractured).
The difference was calculated in the following manner: T
score at V4 minus  T score at baseline, divided by T score at
baseline.
The same calculation was used for the change in T score
from the baseline to V5 (180 days); the mean change in T score
in the proximal forearm (33% of the region of the radius) from
the baseline to V4 and V5 in the two arms (fractured and non-
fractured), with radiological identiﬁcation of callus formation
by means of X-rays.
Bone mineral density (BMD):  BMD  was measured by means
of dual-energy X-ray absorptiometry (DXA), using a GE/Lunar
densitometer (DPXIQ, DPXNT, MD + Prodigy) or Hologic densit-
ometer (QDR 2000, QDR 200 +, QDR 4500, Delphi or Discovery)
on the lumbar spine and proximal femur (femoral neck and
total hip) and the distal region of the forearm (fractured and
non-fractured), at the baseline and then at 90 and 180 days.
The BMD measurements were repeated using DXA  for the dis-
tal region of the forearm (fractured and contralateral).
X-rays: Radiological images of the wrist and arm (fractured
and contralateral) were obtained in two views (posteroanterior
and lateral), at the baseline and 15, 30, 45 and 180 days after
the fracture. The main X-ray parameters for monitoring the
consolidation of the fracture were formation and viewing of
bone bridges along the fracture lines, identiﬁed in the cortex in
each view. Fracture consolidation was deﬁned as the presence
of bone bridges in three of the four cortical images evaluated
in these views.
Quality control procedures were established by means of
training and certiﬁcation of the team involved in using the
densitometry and X-ray equipment, with central analysis of
the tests performed, performed by the coordinator of the
Osteoporosis Research and Diagnosis Center (CEDOES). The
examiners were blinded with regard to the study treatment
administered in each case.
Safety  assessments
Safety was assessed according to the type and severity of the
adverse events that were reported by the patients or observed
in some other way by the investigator.
Deﬁnition  of  the  study  population
All the randomized patients who received at least one dose of
the study medication were included in the intention-to-treat
(ITT) population. The modiﬁed intention-to-treat population
(ITTm) was formed by treated patients who presented changes
in T scores starting from the baseline. The protocol population
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PP) consisted of patients who  were treated without signiﬁcant
iolations of the protocol who had at least one BMD evaluation
n the proximal region of the forearm (33% of the region of the
adius) on the side of the fracture, at the baseline and at V4
90 days).
tatistical  plan
ll the tests applied were performed using SAS v 9.1 and the
tatistical signiﬁcance level was taken to be 5%.
Calculations were based on comparison of the groups
egarding the mean change in BMD  after 90 days of treat-
ent, expressed as a percentage. Power of 80%, signiﬁcance
evel of 5% and discontinuation rate of 10% were used. The
tandard deviation was assumed to be 0.08, with a difference
f interest of 4% between the groups (mean percentage change
n BMD  after 90 days of treatment). Therefore, the estimated
otal number to be recruited was 140 patients (70 per group).
The percentage change (%) in BMD  after 90 days (V4) and
80 days of treatment was calculated in the following manner:
 % change at V4 = [(T-scoreV4 − T-scoreV0)/|T-scoreV0|] * 100
 % change at V5 = [(T-scoreV5 − T-scoreV0)/|T-scoreV0|] * 100
The demographic variables of continuous nature were
escribed separately for the two treatment groups using
eans, standard deviations and ranges. Comparisons
etween the treatment groups were indicated using Student’s test values. The discrete demographic variables were sum-
arized in frequency tables and comparisons between the
reatment groups were based on p values from the chi-square
est or Fisher test, depending on the frequency of the events.
Randomized
N=141
Group GAO
N=71
Visit 4 (90 days)
N=63 
Withdrawn: n=8
Reason for 
withdrawal:
Loss of follow-up: 6
Patient withdrew consent: 1
Lack of adherence*: 1 
Withdrawn: n=4
Reason for 
withdrawal:
Loss of follow-up: 2
Adverse event: 1
Lack of adherence*: 1 
*Use of less than 80% of the study medication
Included
N=180 
Visit 5 (completion
of study)
N=59
Fig. 1 – Distribution ;5 0(3):274–282 277
The Mann–Whitney U test (independent observations)
was applied for comparison between the treatment groups
regarding changes in T-scores (%) from the visit V0 to the visit
V4 and from the visit V0 to the visit V5.
The Wilcoxon signed rank test (dependent observations)
was applied to compare the visits (V4 and V5) regarding
changes in T-score (%), in each treatment group. To compare
the treatment groups between the visits regarding mean T-
scores, a model of analysis of variance (ANOVA) was applied,
with the factors from the treatment groups (Actonel + Oscal
and Oscal), visits (V0, V4 and V5) and the respective interac-
tions between them. To compare the treatment groups with
regard to radiological identiﬁcation of the callus, the chi-
square test or Fisher F test was applied, according to the
frequency of the events.
Results
Patients
The patients’ distribution is presented in Fig. 1. At the end of
the study, 59 patients in GAO and 56 in GO had completed
all the evaluations as planned. A total of 137 patients (70
in GAO and 67 in GO) received at least one dose of study
medication and were evaluated regarding efﬁcacy and safety.
The groups were shown to be homogenous at the baseline
regarding demographic and clinical characteristics (Table 1).
There were no statistically signiﬁcant differences between
the groups in relation to the side on which the fracture
occurred: 36/71 patients (50.7%) had a Colles fracture in the
left forearm in GAO and 38/70 (54.3%) in GO (p = 0.670). For
the majority of the patients, the universal classiﬁcation of
Withdrawn: n=39
Reason for withdrawal:
Did not attend the 
inclusion/exclusion criteria: 35
Away from  home: 2
Patient withdrew:1
Loss of follow-up:1
Group GO
N=70
Visit 4 (90 days)
N=60
Withdrawn = 10
Reason for withdrawal:
Loss of follow-up: 3
Adverse event: 2
New reduction of fracture: 1
Death: 1
Patient withdrew consent: 1
Medical decision: 1
Lack of adherence*: 1
Withdrawn: n=4
Reason for 
withdrawal:
Loss of follow-up: 3
Violation of protocol: 1
Visit 5 
(completion
of study)
N=56
of the patients.
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Table 1 – Demographic characteristics and baseline clinical characteristics.
Demographic characteristics GAO
N = 71
GO
N  = 70
p  value
(GAO vs. GOa)
Age,  years
Mean ± SD 67.1 ± 10.9 64.9 ± 10.4 0.224a
Limits 44–90 44–92
Age stratum, N (%)
<65 years 33 (46.5) 34 (48.6)
≥65 years 38 (53.5) 36 (51.4)
Ethnicity
White 50 (70.4) 57 (81.4) 0.389b
Black 6  (8.5) 4  (5.7)
Mixed 15 (21.1) 9 (12.9)
Weight (kg)
Mean ± SD 58.5  ± 11.5 61.3 ± 12.0 0.1502a
Limits 36–88 34–89
Height (cm)
Mean ± SD 150 ± 6 152 ± 6 0.0482a
Limits 137–165 140–174
Length of time since menopause (years)
Mean ± SD 19.8 ± 12.1 18.3 ± 9.8 0.4392a
Limits 3–55 2–43
Length of time from Colles fracture occurrence to baseline, days
Mean ± SD 3.5  ± 1.7 3.4  ± 1.8 0.580a
a t test for independent variables.
b Chi-square test.
Table 2 – Change in T score in proximal forearm (33%) on fractured side, expressed as percentage, in modiﬁed ITT
population.
V4 V5 p valuea
GAO
No. of patients N = 59 N = 59
Mean ± SD −25.7 ± 40.7 −20.8 ± 39.5
Min/Median/Max −200/−15.2/27.8 −200/−9.1/15.4 0.727
GO
No. of patients N = 57 N = 56
Mean ± SD −31.9 ± 62.5 −32.8 ± 68.0
Min/Median/Max −400/–21.4/75 −366.7/−18.9/90 0.769
p valueb (groups) 0.352 0.069a Wilcoxon signed rank test.
b Mann–Whitney U test.
the Colles fracture was I or II/IIa: 15/71 patients (21.1%) and
46/71 (64.8%), respectively, in GAO; and 16/70 (22.9%) and 43/70
(61.4%), respectively, in GO (p = 0.917).
The BMD  measurement (evaluated by means of the T score)
did not show any statistically signiﬁcant difference between
the treatment groups at the baseline, in forearms diagnosed
with fractures, in forearms without fractures and in the lum-
bar spine, femoral neck and total femur. The majority of the
patients in the two treatment groups used at least 80% of the
total number of pills planned per visit.Findings  on  the  side  of  the  fractured  forearm
On the side of the fractured forearm, a decrease in BMD was
observed (evaluated using the % of the T score) from V0 toV4 (90 days) and V5 (180 days) in the two treatment groups,
ranging from 20.8% to 32.8% (Table 2).
There was a tendency toward greater reduction in BMD
(evaluated using the T score) among the patients in GO. At
V4, this reduction was approximately 15% in GAO and 21% in
GO. At V5, this loss of BMD was approximately 9% in GAO and
19% in GO. No statistically signiﬁcant difference between the
groups was reached at either visit: p = 0.352 and 0.069 for V4
and V5, respectively (Table 2). Likewise, no statistically signif-
icant difference in T score variation was found in comparing
V4 and V5 in the two groups (p = 0.727 and 0.769 for GAO and
GO, respectively).
The same tendency toward greater reduction in BMD was
observed in the protocol population (PP) for GO, in comparison
with GAO, and there was no statistically signiﬁcant difference
between the groups (p = 0.110) (Table 3).
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Table 3 – Change in T score in proximal forearm (33%) on
fractured side, expressed as percentage, in PP
population.
Groups V4 p value (groups)a
GAO
No. of patients N = 45
Mean ± SD −24.6 ± 41.9
Min/Median/Max −200/−15.2/27.8
GO
No. of patients N = 46
Mean ± SD −27.4 ± 30.8
Min/Median/Max −166.7/−23.0/20% 0.110
t
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Table 5 – Loss of BMD  in the proximal forearm (33% of
radius) between visits V0 and V5 (day 180), in modiﬁed
ITT population.
GAO GO
Fractured
N 59 56
Loss of BMD 39 (66.1%) 43 (76.8%)
Mean ± SD −0.5  (0.4) −0.7 (0.4)
Non-fractured
N 59 56
Loss of BMD 25 (42.4%) 24 (42.9%)
Mean ± SD −0.3 (0.3) −0.3 (0.2)
p valuea 0.010 0.0003a Mann–Whitney U test.
From V0 to V4 (day 90), most of the patients in the two
reatment groups presented loss of BMD: 46/63 (73.0%) in GAO
nd 46/60 (76.7%) in GO. The mean ± SD for the loss of BMD
as −0.5 (0.4) in GAO and −0.7 (0.4) in GO. Comparing V0 with
5 (day 180), a loss of BMD  could be seen in 39/59 patients
66.1%) in GAO and in 43/56 (76.8%) patients in GO. The mean
 DP of the difference in BMD  between V0 and V5 was −0.5
0.4) for GAO and −0.7 (0.4) for GO.
indings  on  the  non-fractured  side
n the non-fractured forearm, the BMD  evaluated according to
he change in T score (%) from V0 until the visits V4 and V5
anged from 4.2% upwards (an increase from V0 to V4, i.e. day
0) to −6.0% downwards (a reduction from V0 to V5, i.e. day
80) (Table 4).
At V4, the increase in BMD  (evaluated according to the T
core) was seen to be greater in GO (4.2%) than in GAO (1.9%);
nd at V5, there was a reduction in BMD  (evaluated according
o the T score) in the two groups. It was greater in GO (−5.7%)
han in GAO (−2.2%). No statistically signiﬁcant differences
ere observed between the treatment groups at the two visits
r between the visits for the two treatment groups (Table 4).
Furthermore, approximately 30% and 42% of the patients
n the two treatment groups showed losses of BMD from the
aseline to V4 (day 90) and to V5 (day 180), respectively.
In relation to the proportion of patients with losses of
MD  at V4, there was a statistically signiﬁcant difference
Table 4 – Change in T score in proximal forearm (33%) on non-f
population.
V4 
GAO
No. of patients N = 59 
Mean ± SD 1.9 ± 17.4 
Min/Median/Max −36.4/0/79.2 
GO
No. of patients N = 57 
Mean ± SD 4.2 ± 37.4 
Min/Median/Max −142.9/3.8/150 
p valueb (groups) 0.438 
a Wilcoxon signed rank test.
b Mann–Whitney U test.a Chi-square test.
between the fractured and non-fractured sides in the two
treatment groups (GAO and GO; p < 0.0001 for both). This dif-
ference in pattern observed in the forearms between the sides
was probably related to the immobilization of the fractured
side (Table 5).
The ANOVA model compared the mean T scores in the
two treatment groups between the visits, using the treatment
group (GAO or GO) and the visits (V0, V4 and V5) as factors,
along with their respective interactions. There was no evi-
dence of signiﬁcant interaction between the factors, either for
the side with the fracture (p = 0.134) or for the non-fractured
side (p = 0.982). This suggests that the two  treatment groups
had similar patterns over the course of time (Figs. 2 and 3).
On the side with the fracture, there was a statistically sig-
niﬁcant difference between the visits, such that the mean T
scores were signiﬁcantly lower at V4 and V5, in relation to
V0 (p < 0.001), although no differences were found between
the treatment groups (p = 0.825) (Fig. 2). On the side with the
fracture, there was no evidence of any statistically signiﬁ-
cant variation between the groups (p = 0.554) or visits (p = 0.081)
(Fig. 3).
Radiological  evaluationThe results from radiological identiﬁcation of the callus over
the course of the visits did not show any evidence of any sig-
niﬁcant difference between the treatment groups at the visits
ractured side, expressed as percentage, in modiﬁed ITT
V5 p valuea(visits)
N = 59
−2.2 ± 28.2
−133.3/0/75.5 0.223
N = 56
−5.7 ± 29.8
−142.9/0/34.6 0.128
0.861
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Fig. 2 – Results from the ANOVA model for the fractured side.
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A moFig. 3 – Results from the ANOV
V1 (p = 0.674), V2 (p = 0.755) and V3 (p = 0.749), with regard to the
proportion of the patients in whom the callus was identiﬁed
on X-rays. At the other visits (V4 and V5), the callus was seen
by means of X-rays in almost all the patients, in both groups,
and no statistical comparison was made.
Safety
In GAO, 23/71 randomized patients (32.4%) reported that at
least one adverse event occurred during the study period,
totaling 34 such events. In GO, 23/70 randomized patients
(32.9%) reported that adverse events occurred during the study
period, totaling 41 such events. Three adverse events were
considered by the investigator to be serious. In GAO, one case
of renewed fracturing of the wrist was reported. This was con-
sidered to be of moderate intensity and needed hospitalization
and surgery for external ﬁxation to be implemented. It was
reported that the patient had recovered. In GO, two cases of
adverse events occurred. One of these consisted of a hypoe-
choic accumulation in the right calf, which was considered to
be of moderate intensity. This case required hospitalizationdel for the non-fractured side.
and the patient was still recovering at the time of this report.
The other adverse event comprised cardiorespiratory arrest,
which occurred at the patient’s home, was of severe intensity
and resulted in death.
None of these three adverse events was considered by the
investigator to be related to the study medication. In GO, both
of the adverse events led to interruption of the treatment. For
the patient in GAO, administration of the study medication
was not immediately stopped because of the adverse event,
but the event led to withdrawal from the study.
Overall, the treatments were withdrawn in the cases of
three patients because of adverse events relating to the treat-
ment: 1/71 patients (1.4%) in GAO presented acute gastritis
and one patient (1.4%) in GO presented epigastric burning
and discomfort and another patient (1.4%) presented gastric
pain. In addition, another two  patients were withdrawn from
the study, but without any relationship with the study treat-
ment. In GO, one case of cardiorespiratory arrest was reported;
another patient was reported to have had a psychotic episode
and a further patient presented a hypoechoic accumulation in
the right calf.
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iscussion
n the present study, after 90 days of risedronate use, no signiﬁ-
ant variation in the loss of BMD  was seen in the fractured arm,
r in the non-fractured arm. The same pattern was observed
fter 180 days of treatment, which suggests that risedronate
as a protective effect due to the immobilization.
Several medications have been used to improve bone
onsolidation, both for accelerating the process and also
or improving the quality of the bone callus, i.e. through
mproving the microarchitecture, volume and biomechanical
trength of the callus. These medications include strontium
anelate and drugs that act on the Wnt  signaling system, such
eriparatide and the antibodies anti-sclerostin and DKK-1.12–15
ome medications have been recognized as harmful to cal-
us formation and these include corticoids, chemotherapeutic
gents, antibiotics, anti-inﬂammatory agents, anticoagulants
nd anticonvulsants.16
However, bisphosphonates are the drugs that have been
tudied most. These favor formation of a more  voluminous
allus with mineralization and make the callus mechani-
ally more  competent, but with a slower remodeling rate.17–22
nother factor discussed in the literature has been the time
t which bisphosphonate use should start, after a fracture has
ccurred. Some evidence favors starting to use bisphospho-
ates 15 days after the event, while other evidence suggests
hat, independent of the time at which they are admin-
stered, they do not interfere with bone consolidation or
ith postoperative healing following occurrences of osteo-
orotic fractures.23,24 The time taken to reach consolidation
s unrelated to the severity of the osteoporosis or the type
f fracture.25 Therapy using bisphosphonates can be contin-
ed after occurrences of fractures of the distal radius, without
eleterious clinical effects on consolidation.26
When used for long periods, bisphosphonates may
ncrease the occurrences of micro and macrofractures in ani-
als and humans. They also give rise to preferential fracture
ites. However, biomechanical gains regarding the bone cal-
us are observed (size and external diameter). It seems that
he organism compensates for the negative effect of the med-
cation and modulates the morphology of the callus so as to
btain better biomechanical function (mechanostat).27
The effects of risedronate have been studied both in rela-
ion to improvement of bone mineral density and fracture
revention in patients with osteoporosis and in relation to
se during bone consolidation. It has been observed that
isedronate does not interfere negatively with bone callus
ormation and can be used without deleterious effects on con-
olidation. On the contrary, it increases the volume of the
allus and its biomechanical resistance.28,29
The BMD  of 33% of the radius on the fractured side at
he end of six months (V5) presented a negative change of
2.8% in the Oscal group and only 20.8% in the Actonel + Oscal
roup, which showed that risedronate had a tendency toward
aving a protective effect against loss of BMD caused by post-
racture immobilization (p = 0.069). Even though there was no
tatistically signiﬁcant difference between the two groups, it
as seen that there was lower loss of BMD (evaluated using
 scores) in the group treated with Actonel + Oscal (mean;5 0(3):274–282 281
decrease of −0.5), in relation to the group that used Oscal alone
(mean decrease of −0.7), as shown in Table 5. This was possibly
due to the great variability of the data.
The BMD  of 33% of the radius on the non-fractured side at
the end of six months (V5) presented a negative change of 5.7%
in GO and only 2.2% in GAO, with a difference of 3% in favor
of risedronate. However, there was no statistically signiﬁcant
difference (p = 0.861) (Table 4).
As shown in Fig. 2, the initial BMD of 33% of the radius
on the fractured side (measured using the T score) decreased
signiﬁcantly (p < 0.001) during the treatment (from V0 to V5),
while this difference was not observed on the non-fractured
side. This shows the signiﬁcant inﬂuence of immobiliza-
tion of a fracture on bone loss. Regarding the proportion of
patients with loss of BMD at V5, there was a statistically sig-
niﬁcant difference between the fractured and non-fractured
sides, for both treatment groups (GAO, p = 0.010; GO, p = 0.0003)
(Table 5). This pattern of difference observed between the
groups was probably related to immobilization of the fractured
side (Table 5). These data show that risedronate provided pro-
tection in relation to loss of BMD  during the immobilization
of a limb (osteoporosis of disuse), which is discussed in other
studies.30
There was no signiﬁcant difference in radiological identiﬁ-
cation of the bone callus at the times of the visits (V1 to V5),
or between the treatment groups. Thus, use of risedronate in
our study did not present any negative clinical effect on bone
consolidation. In most of the patients, radiological identiﬁca-
tion of the callus occurred at V3, with a similar pattern in the
two groups. Furthermore, the safety proﬁle of risedronate was
shown to be similar to that of the control group.
Limitations of the study: Given that this study was designed
without comparison with placebo, we  believe that there may
have been an important effect on BMD, since the tests were
evaluated centrally, as described in the methodology. How-
ever, based on the well-established side effects that have been
described previously for this class of medications, an effect in
interpreting the safety data cannot be totally ruled out.
Conclusions
Postmenopausal women with Colles fractures who  received
sodium risedronate plus calcium and vitamin D,  in compar-
ison with calcium and vitamin D only, did not show any
signiﬁcant difference regarding loss of BMD in the fractured
and non-fractured forearm after 90 days (primary objective)
and 180 days (secondary objective). Risedronate was shown
to have a tendency toward a protective effect regarding loss
of BMD due to immobilization. The time taken to reach frac-
ture consolidation was unaffected and the two groups showed
similar safety patterns.
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